These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27187883)

  • 1. [Therapeutic Options in Vitreomacular Traction With or Without a Macular Hole].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Klin Monbl Augenheilkd; 2016 May; 233(5):622-30. PubMed ID: 27187883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Initial clinical experience in the treatment of vitreomacular traction and macular holes with ocriplasmin].
    Lommatzsch AP; Gutfleisch M; Dietzel M; Heimes B; Spital G; Böhme M; Bornfeld N; Pauleikhoff D
    Klin Monbl Augenheilkd; 2014 Sep; 231(9):909-14. PubMed ID: 24788606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical Results in Ocriplasmin Candidates With Symptomatic Vitreomacular Traction Syndrome.
    Vasquez DH; Altamirano JC; Casaus A; Del Valle RA; Gonzalez R; Gonzalez-De La Rosa A; Navarro-Partida J; Vasquez MA; Santos A
    Curr Eye Res; 2018 Feb; 43(2):208-212. PubMed ID: 29111823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of intravitreal ocriplasmin treatment for vitreomacular traction in clinical practice.
    Schumann RG; Langer J; Compera D; Luedtke K; Schaumberger MM; Kreutzer T; Mayer WJ; Wolf A; Priglinger SG
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2081-2089. PubMed ID: 28755165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment.
    Steel DH; Lotery AJ
    Eye (Lond); 2013 Oct; 27 Suppl 1(Suppl 1):S1-21. PubMed ID: 24108069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
    Jackson TL; Regillo CD; Girach A; Dugel PU;
    Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the individual probability of macular hole closure following intravitreal ocriplasmin injections for vitreomacular traction release using baseline characteristics.
    Bertelmann T; Berndzen L; Raber T; Pfeiffer S; Leha A; Paul C; Feltgen N; Bemme S
    Sci Rep; 2021 Dec; 11(1):24096. PubMed ID: 34916576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNEUMATIC VITREOLYSIS VERSUS PARS PLANA VITRECTOMY IN FOCAL SYMPTOMATIC VITREOMACULAR TRACTION SYNDROME: A Randomized Trial.
    Kumar V; Sonkar R; Verma S; Azad SV; Chawla R; Venkatesh P; Vohra R; Kumar A
    Retina; 2022 Jul; 42(7):1277-1283. PubMed ID: 35723920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC VITREOMACULAR TRACTION: A Natural History Study From the Pan American Collaborative Retina Study Group.
    Wu L; Zas M; Berrocal MH; Arevalo JF; Figueroa M; Rodriguez F; Serrano M; Graue F; Alezzandrini A; Gallego-Pinazo R; Roca JA; Iglicki M; Dalma-Weishauz J; Kozak I; Collado A; Badal J; Maia M; Salcedo-Villanueva G; Quiroz-Mercado H; Fromow-Guerra J; Lozano-Rechy D; Avila M; Chhablani J
    Retina; 2016 Oct; 36(10):1913-8. PubMed ID: 26966868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole.
    Zandi S; Freiberg F; Vaclavik V; Pfister IB; Traine PG; Kaya C; Michels S; Garweg JG
    J Ocul Pharmacol Ther; 2020 Mar; 36(2):126-132. PubMed ID: 31934816
    [No Abstract]   [Full Text] [Related]  

  • 17. INTRAVITREAL OCRIPLASMIN IN CLINICAL PRACTICE: Predictors of Success, Visual Outcomes, and Complications.
    Feng HL; Roth DB; Hasan A; Fine HF; Wheatley HM; Prenner JL; Shah SP; Modi KK; Feuer WJ
    Retina; 2018 Jan; 38(1):128-136. PubMed ID: 28106706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
    Shaikh M; Miller JB; Papakostas TD; Husain D
    Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diseases of the vitreo-macular interface].
    Koerner F; Garweg J
    Klin Monbl Augenheilkd; 1999 May; 214(5):305-10. PubMed ID: 10420374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.